Nanotechnology Now





Heifer International

Wikipedia Affiliate Button


DHgate

Home > Press > OctoPlus publishes third quarter business update

Abstract:
OctoPlus N.V. ("OctoPlus" or the "Company") (Euronext: OCTO), today publishes a business update for the third quarter of 2009.

OctoPlus publishes third quarter business update

The Netherlands | Posted on November 9th, 2009

Highlights

Financial
- Positive operating result (EBIT) achieved for the third quarter, driven by strong third quarter revenues and cost savings
- Revenues for the first nine months of 2009 are well in line with guidance for the full year of €19 million

Operational
- Two substantial contract development service contracts signed in August and September, including one with a European mid-sized pharma company
- Expansion of drug delivery evaluation contract with an existing client signed in September
- Phase IIb clinical study with Locteron® ongoing: OctoPlus awaits top-line results from licensee Biolex
- Restructuring of the organisation is proceeding as planned

Strategy
- International adoption of OctoPlus' controlled release technology with growing number of evaluations by both small and large (bio)pharmaceutical companies

Outlook
- OctoPlus reiterates the expected 2009 revenues of approximately €19 million

Simon Sturge, CEO of OctoPlus comments: "I am delighted to be able to report an operating profit for the third quarter of 2009, whereas we reiterate that we do not expect to achieve a positive cash flow in the second half of the year. Revenues in the first nine months of 2009 have been in line with expectations and we are very excited about the additional clients that have decided to work with us during the third quarter. Our restructured organisation has positioned the Company for a promising future."

This document may contain certain forward-looking statements relating to the business, financial performance and results of OctoPlus and the industry in which it operates. These statements are based on OctoPlus' current plans, estimates and projections, as well as its expectations of external conditions and events. In particular the words "expect", "anticipate", "predict", "estimate", "project", "plan", "may", "should", "would", "will", "intend", "believe" and similar expressions are intended to identify forward-looking statements. We caution investors that a number of important factors, and the inherent risks and uncertainties that such statements involve, could cause actual results or outcomes to differ materially from those expressed in any forward-looking statements. In the event of any inconsistency between an English version and a Dutch version of this document, the English version will prevail over the Dutch version.

####

About OctoPlus N.V.
OctoPlus is a drug delivery service company committed to the creation of improved pharmaceutical products that are based on OctoPlus' proprietary drug delivery technologies and have fewer side effects, improved patient convenience and a better efficacy/safety balance than existing therapies. OctoPlus focuses on the development of long-acting, controlled release versions of known protein therapeutics, other drugs, and vaccines on behalf of its clients.

The clinically most advanced product incorporating our technology is Biolex Therapeutics' lead product Locteron®, a controlled release formulation of interferon alpha for the treatment of chronic hepatitis C. OctoPlus licensed Locteron exclusively to Biolex in October 2008. Locteron is being manufactured for Biolex by OctoPlus and is currently in Phase IIb clinical studies.

In addition, OctoPlus is a leading European provider of advanced drug formulation and clinical scale manufacturing services to the pharmaceutical and biotechnology industries, with a focus on difficult-to-formulate active pharmaceutical ingredients.

OctoPlus is listed on Euronext Amsterdam by NYSE Euronext under the symbol OCTO. For more information about OctoPlus, please visit our website www.octoplus.nl.

For more information, please click here

Contacts:
Rianne Roukema
Corporate Communications
+31 (71) 524 1071

Copyright © OctoPlus N.V.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Chitosan coated, chemotherapy packed nanoparticles may target cancer stem cells June 30th, 2015

BASF and Fraunhofer IPMS-CNT jointly develop electronic materials June 30th, 2015

Researchers from the UCA, key players in a pioneering study that may explain the origin of several digestive diseases June 30th, 2015

Oxford Instruments’ TritonXL Cryofree dilution refrigerator selected for the Oxford NQIT Quantum Technology Hub project June 30th, 2015

Nanomedicine

Chitosan coated, chemotherapy packed nanoparticles may target cancer stem cells June 30th, 2015

Researchers from the UCA, key players in a pioneering study that may explain the origin of several digestive diseases June 30th, 2015

Efforts to Use Smart Nanocarriers to Cure Leukemia Yield Promising Results June 29th, 2015

Chivalrous Knight Does Pro Bono June 27th, 2015

Announcements

BASF and Fraunhofer IPMS-CNT jointly develop electronic materials June 30th, 2015

Graphene flexes its electronic muscles: Rice-led researchers calculate electrical properties of carbon cones, other shapes June 30th, 2015

Researchers from the UCA, key players in a pioneering study that may explain the origin of several digestive diseases June 30th, 2015

Oxford Instruments’ TritonXL Cryofree dilution refrigerator selected for the Oxford NQIT Quantum Technology Hub project June 30th, 2015

Financial Reports

Aspen Aerogels to Webcast 2015 Annual Meeting of Stockholders June 11th, 2015

Industrial Nanotech, Inc. Provides Update June 8th, 2015

PEN Inc. Announces First Quarter Financial Results: Investor Webcast and Business Update Set for May 21, 1 pm EDT May 13th, 2015

Arrowhead to Report Fiscal 2015 Second Quarter Financial Results May 4th, 2015

Alliances/Trade associations/Partnerships/Distributorships

Graphene breakthrough as Bosch creates magnetic sensor 100 times more sensitive than silicon equivalent June 28th, 2015

Dyesol Joins Solliance as an Industrial Partner June 17th, 2015

Framework materials yield to pressure June 11th, 2015

The European project SVARNISH, a step forward in the food packaging sector June 11th, 2015

New-Contracts/Sales/Customers

Oxford Instruments’ TritonXL Cryofree dilution refrigerator selected for the Oxford NQIT Quantum Technology Hub project June 30th, 2015

Centre for Process Innovation pilots Beneq’s breakthrough roll-to-roll ALD system for moisture barrier films June 3rd, 2015

Argonne chooses Beneq’s TFS 500 Atomic Layer Deposition System: Modularity and flexibility make for a natural choice May 14th, 2015

New JEOL E-Beam Lithography System to Enhance Quantum NanoFab Capabilities May 6th, 2015

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More










ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project